Please select the option that best describes you:
If a patient with HER2+ uterine serous carcinoma recurs while on maintenance trastuzumab, would you continue trastuzumab with second line chemotherapy?
Given data from metastatic breast cancer trials that show benefit with continuing trastuzumab despite progression.
Answer from: at Community Practice
I advise against extrapolating data from breast cancer therapies to endometrial cancer. There is no clinical trial supporting the administration of trastuzumab (or other anti-HER2 therapy) with second line chemotherapy after progression on maintenance trastuzumab in serous endometrial cancer. Rather...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Extrapolating from HER2+ (ERBB2-amplified) breast cancer, treatment is a HER2-targeted agent plus cytotoxic chemotherapy. Before we had HER2 tyrosine kinase inhibitors (neratinib, lapatinib, tucatinib) and antibody-drug conjugates (trastuzumab emtansine, trastuzumab deruxtecan) for HER2+ breast...